NodThera Ltd, a biotech developing novel treatments for chronic inflammatory diseases, has appointed Daniel Swisher as chief executive officer to strengthen the company’s commercial capabilities. Mr Swisher succeeds Alan Watt, NodThera’s founder, who was serving as interim CEO and who has become president and chief scientific officer. Mr Swisher joins NodThera from Jazz Pharmaceuticals where he was president and chief operating officer and brings over 30 years’ experience in the life sciences industry. NodThera is developing treatments targeting the NLRP3 inflammasome and has two lead clinical candidates.
NodThera announced the appointment on 26 May 2024
Copyright 2024 Evernow Publishing Ltd